Abbott Laboratories Fourth Quarter Earnings Report Near

S&P 500 (NYSE:SPY) component Abbott Laboratories (NYSE:ABT) will unveil its latest earnings on Wednesday, January 25, 2012. Abbott Laboratories is a pharmaceuticals health care company, whose main line of business is in the discovery, development, manufacture, and sale of a broad range of health care products. Its customers include wholesalers, hospitals and commercial laboratories.

Abbott Laboratories Earnings Preview Cheat Sheet.

Wall St. Earnings Expectations: The average estimate of analysts is for profit of $1.44 per share, a rise of 10.8% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. For the year, analysts are projecting net income of $4.65 per share, a rise of 11.5% from last year.

Past Earnings Performance: Last quarter, the company beat estimates by one cent, coming in at profit of $1.18 a share versus the estimate of net income of $1.17 a share. It marked the fourth straight quarter of beating estimates.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: On average, analysts predict $10.61 billion in revenue this quarter, a rise of 6.4% from the year ago quarter. Analysts are forecasting total revenue of $39.03 billion for the year, a rise of 11% from last year’s revenue of $35.17 billion.

Analyst Ratings: Analysts seem relatively indifferent about Abbott Laboratories Com Stk NPV with 11 of 21 analysts surveyed maintaining a hold rating.

A Look Back: In the third quarter, profit fell 66% to $303.2 million (19 cents a share) from $890.7 million (57 cents a share) the year earlier, but exceeded analyst expectations. Revenue rose 13.2% to $9.82 billion from $8.67 billion.

Key Stats:

Revenue has risen the past four quarters. Revenue rose 9% in the second quarter from the year earlier, climbed 17.4% in the first quarter from the year-ago quarter and 13.4% in the fourth quarter of the last fiscal year.

The decrease in profit in the third quarter came after net income rose in the previous quarter. In the second quarter, net income rose 50.4%.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co., Inc. (NYSE:MRK), Medtronic, Inc. (NYSE:MDT), Boston Scientific Corp. (NYSE:BSX), and Sanofi-Aventis SA (NYSE:SNY).

Stock Price Performance: During November 18, 2011 to January 19, 2012, the stock price had risen $2.37 (4.5%) from $53.06 to $55.43. The stock price saw one of its best stretches over the last year between October 3, 2011 and October 12, 2011 when shares rose for eight-straight days, rising 5.3% (+$2.61) over that span. It saw one of its worst periods between July 22, 2011 and August 2, 2011 when shares fell for eight-straight days, falling 5.2% (-$2.70) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?